Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes
Authors:
- Heather YoungHYHeather Young
- François ChappuisFCFrançois Chappuis
- Gerardo PriottoGPGerardo Priotto
- Marie-Eve RaguenaudMRMarie-Eve Raguenaud
- Francesco ChecchiFCFrancesco Checchi
- 1 March 2009
- journal article
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
- Vol. 103 (3) , 280-290
Abstract
This paper describes the effectiveness of first-line regimens for stage 2 human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense infection in nine Médecins Sans Frontières HAT treatment programmes in Angola, Republic of Congo, Sudan and Uganda. Regimens included eflornithine and standard- and short-course melarsoprol. Outcomes for 10461 naïve stage 2 patients fitting a standardised case definition and allocated to one of the above regimens were analysed by intention-to-treat analysis. Effectiveness was quantified by the case fatality rate (CFR) during treatment, the proportion probably and definitely cured and the Kaplan-Meier probability of relapse-free survival at 12 months and 24 months post admission. The CFR was similar for the standard- and short-course melarsoprol regimens (4.9% and 4.2%, respectively). The CFR for eflornithine was 1.2%. Kaplan-Meier survival probabilities varied from 71.4-91.8% at 1 year and 56.5-87.9% at 2 years for standard-course melarsoprol, to 73.0-91.1% at 1 year for short-course melarsoprol, and 79.9-97.4% at 1 year and 68.6-93.7% at 2 years for eflornithine. With the exception of one programme, survival at 12 months was >90% for eflornithine, whilst for melarsoprol it was <90% except in two sites. Eflornithine is recommended where feasible, especially in areas with low melarsoprol effectiveness.Keywords
This publication has 20 references indexed in Scilit:
- Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort studyBMJ, 2008
- Eliminating Human African Trypanosomiasis: Where Do We Stand and What Comes Next?PLOS Medicine, 2008
- Human African trypanosomiasis: pharmacological re‐engagement with a neglected diseaseBritish Journal of Pharmacology, 2007
- Equivalence Trial of Melarsoprol and Nifurtimox Monotherapy and Combination Therapy for the Treatment of Second‐StageTrypanosoma brucei gambienseSleeping SicknessThe Journal of Infectious Diseases, 2007
- Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of Congo2006
- The risk factors for relapse among patients with African trypanosomiasis in Daloa, Cote d'IvoireTropical Doctor, 2006
- Eflornithine Is Safer than Melarsoprol for the Treatment of Second-Stage Trypanosoma brucei gambiense Human African TrypanosomiasisClinical Infectious Diseases, 2005
- Trypanosomiasis Relapse after Melarsoprol Therapy, Democratic Republic of Congo, 1982–2001Emerging Infectious Diseases, 2005
- Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sicknessThe Lancet, 2004
- Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapyTransactions of the Royal Society of Tropical Medicine and Hygiene, 1994